BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10561012)

  • 1. Current treatment of follicular low-grade lymphomas.
    Peterson BA
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):2-11. PubMed ID: 10561012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas.
    Bremer K
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):603-9. PubMed ID: 12458340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicular lymphoma: a therapeutic update.
    Italiano A; Thyss A
    Bull Cancer; 2005 Oct; 92(10):E57-64. PubMed ID: 16266867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
    Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic advances for indolent lymphomas].
    Ogura M
    Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Follicular lymphoma].
    Illés A; Krenács L; Borbényi Z
    Orv Hetil; 2003 Nov; 144(46):2253-61. PubMed ID: 14702920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
    Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant interferon-alpha therapy in patients with follicular lymphoma.
    Ozer H; Wiernik PH; Giles F; Tendler C
    Cancer; 1998 May; 82(10):1821-30. PubMed ID: 9587113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indolent lymphomas: current and emerging treatment approaches.
    Maloney D; Kahl BS; Dreyling M
    Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
    Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment of follicular and low-grade non-Hodgkin's lymphoma.
    Linch D
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S5-9. PubMed ID: 11508934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
    Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH
    J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hematological neoplasm--how to treat low-grade lymphomas].
    Hirano M
    Rinsho Ketsueki; 1995 May; 36(5):465-70. PubMed ID: 7783352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
    Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
    Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of hematopoietic cell transplantation for follicular non-Hodgkin's lymphoma.
    Laport GG
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):59-65. PubMed ID: 16399587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA
    J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose therapy and transplantation in non-Hodgkin's lymphoma.
    Morrison VA; Peterson BA
    Semin Oncol; 1999 Feb; 26(1):84-98. PubMed ID: 10073565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
    Turturro F
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.